Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts.
US FDA
biopharmaceutical properties
carboxylic acid counterions
enhanced bioavailability
pharmaceutical salts
weakly basic drugs
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
25
05
2021
accepted:
01
07
2021
pubmed:
25
7
2021
medline:
18
1
2022
entrez:
24
7
2021
Statut:
ppublish
Résumé
Salification is one of the powerful and widely employed approaches to improve the biopharmaceutical properties of drugs. The FDA's eighty-year trajectory of new drug approvals depicts around one-third of the drugs clinically used as their pharmaceutical salts. Among various cationic and anionic counterions used in FDA-approved pharmaceutical salts, the carboxylic acids have significantly contributed. A total of 94 pharmaceutical salts discovered during 1943-2020 comprises carboxylic acids as counterions with a major contribution of acetate, maleate, tartrate, fumarate, and succinate. Hydrocodone tartrate is the first FDA-approved carboxylate salt approved in 1943. Overall, the analysis shows that fifteen carboxylic acid counterions are present in FDA-approved pharmaceutical salts with a major share of acetate (18 drugs). This review provides an account of FDA-approved carboxylate salts from 1939 to 2020. The decade-wise analysis indicates that 1991-2000 contributed a maximum number of carboxylate salts (24) and least (3) in 1939-1950. The technical advantage of carboxylate salts over free-base or other counterions is also discussed. Graphical Abstract.
Identifiants
pubmed: 34302256
doi: 10.1007/s11095-021-03080-2
pii: 10.1007/s11095-021-03080-2
doi:
Substances chimiques
Carboxylic Acids
0
Pharmaceutical Preparations
0
Salts
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1326Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Paulekuhn GS, Dressman JB, Saal C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange book database. J Med Chem. 2007;50(26):6665–72.
pubmed: 18052022
doi: 10.1021/jm701032y
Saal C, Becker A. Pharmaceutical salts: a summary on doses of salt formers from the Orange book. Eur J Pharm Sci. 2013;49(4):614–23.
pubmed: 23747999
doi: 10.1016/j.ejps.2013.05.026
Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603–16.
pubmed: 17619064
doi: 10.1016/j.addr.2007.05.010
Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm. 1994;105:209–17.
doi: 10.1016/0378-5173(94)90104-X
Khorana AB. A controlled double blind comparative study of single dose administration of imipramine pamoate and divided dose of imipramine hydrochloride in depressive illness. Indian J Physiol Pharmacol. 1981;25(4):331–8.
pubmed: 7042559
Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci. 1977;66(1):1–19.
pubmed: 833720
doi: 10.1002/jps.2600660104
Bharate SS. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019. Drug Discov Today. 2021;26(2):384–98.
pubmed: 33221522
doi: 10.1016/j.drudis.2020.11.016
Howell WH, Holt E. Two new factors in blood coagulation—heparin and pro-antithrombin. Am J Phys. 1918;47:328–41.
doi: 10.1152/ajplegacy.1918.47.3.328
Lim GB. Milestone 1: discovery and purification of heparin. Nat Rev Cardiol. 2017. https://doi.org/10.1038/nrcardio.2017.171 .
Walkling WD, Reynolds BE, Fegely BJ, Janicki CA. Xilobam: effect of salt form on pharmaceutical properties. Drug Dev Ind Pharm. 1983;9:809–19.
doi: 10.3109/03639048309039889
Clayton D, Leslie A. The bioavailability of erythromycin stearate versus enteric-coated erythromycin base when taken immediately before and after food. J Int Med Res. 1981;9:470–7.
pubmed: 7319133
doi: 10.1177/030006058100900608
Sikora K, Jaskiewicz M, Neubauer D, Migon D, Kamysz W. The role of counter-ions in peptides-an overview. Pharmaceuticals (Basel). 2020;13(12):442.
Boullerne AI, Polak PE, Braun D, Sharp A, Pelligrino D, Feinstein DL. Effects of peptide fraction and counter ion on the development of clinical signs in experimental autoimmune encephalomyelitis. J Neurochem. 2014;129(4):696–703.
pubmed: 24471474
doi: 10.1111/jnc.12664
Trudell JR, Ardies CM, Anderson WR. Antibodies raised against trifluoroacetyl-protein adducts bind to N-trifluoroacetyl-phosphatidylethanolamine in hexagonal phase phospholipid micelles. J Pharmacol Exp Ther. 1991;257(2):657–62.
pubmed: 2033512
You Q, Cheng L, Ju C. Generation of T cell responses targeting the reactive metabolite of halothane in mice. Toxicol Lett. 2010;194(3):79–85.
pubmed: 20156533
pmcid: 2866171
doi: 10.1016/j.toxlet.2010.02.009
Dutta AS, Furr BJA, Giles MB. Polypeptide. US4100274A (May 11, 1976), Imperial Chemical Industries Ltd., 1976.
Balkovec JM, Hughes DL, Masurekar PS, Sable CA, Schwartz RE, Singh SB. Discovery and development of first in class antifungal caspofungin (CANCIDAS(R))--a case study. Nat Prod Rep. 2014;31(1):15–34.
pubmed: 24270605
doi: 10.1039/C3NP70070D
Miller E, Rock HJ, Moore ML. Substituted sulfanilamides-III, N4-acyl-N1-hydroxy derivatives. J Am Chem Soc. 1940;62:2099–103.
doi: 10.1021/ja01865a053
Mendelson JA, Pratt HJ, Amato JJ, Lieberman MK, Hamm TE, Gruber RP, et al. Mafenide hydrochloride and mafenide acetate in spray and ointment forms as topical therapy of C. perfringens contaminated massive wounds: experimental study. J Trauma. 1970;10(12):1132–44.
pubmed: 4320694
doi: 10.1097/00005373-197012000-00005
Barillo DJ. Using mafenide acetate in acute and chronic wounds. Ostomy Wound Manage. 2002;Suppl:5–10.
Jirman J, Richter J. New salts of bazedoxifene. EP2185510B1, US20100240888A1 (July 25, 2007), Zentiva KS, 2007.
Hudak JM, Banitt EH, Schmid JR. Discovery and development of flecainide. Am J Cardiol. 1984;53(5):17B–20B.
pubmed: 6364768
doi: 10.1016/0002-9149(84)90495-8
pmcid: 6364768
Lim KS, Cho JY, Jang IJ, Kim BH, Kim J, Jeon JY, et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol. 2008;66(5):660–6.
pubmed: 18754843
pmcid: 2661981
Barth WE. 2-Hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines. US3700681A (Feb 16, 1971), Pfizer Inc 1971.
Demerson C, Iera S, Ali KA. Crystalline polymorph of a bazedoxifene acetate. WO2005100316A1 (April 7, 2004), Wyeth. 2004.
Anonymous. Assessment report for conbriza. European Medicines Agency, London, UK; DocRef:EMEA/CHMP/660889/2008. 2009.
McKeand W. Pharmacokinetics, dose proportionality, and bioavailability of Bazedoxifene in healthy postmenopausal women. Clin Ther. 2017;39(9):1769–79.
pubmed: 28756067
doi: 10.1016/j.clinthera.2017.07.012
pmcid: 28756067
Dwyer PJ, Weir PJ, Ireland DS, Taylor CG. Compatibility of cyclizine lactate solutions with chloride ion. Anal Proc. 1994;31:157–8.
doi: 10.1039/ai9943100157
Ishizaki J, Yokogawa K, Nakashima E, Ichimura F. Relationships between the hepatic intrinsic clearance or blood cell-plasma partition coefficient in the rabbit and the lipophilicity of basic drugs. J Pharm Pharmacol. 1997;49(8):768–72.
pubmed: 9379353
doi: 10.1111/j.2042-7158.1997.tb06109.x
pmcid: 9379353
Wilson TD. Pentazocine. In: Florey K, editor. Analytical profiles of drug substances: Academic Press; 1984. p. 361–416.
doi: 10.1016/S0099-5428(08)60197-5
Miller RR. Clinical effects of pentazocine in hospitalized medical patients. J Clin Pharmacol. 1975;15(2–3):198–205.
pubmed: 1123460
doi: 10.1002/j.1552-4604.1975.tb02357.x
Francis LJ, Houston JB, Hallifax D. Impact of plasma protein binding in drug clearance prediction: a data base analysis of published studies and implications for in vitro-in vivo extrapolation. Drug Metab Dispos. 2021;49(3):188–201.
pubmed: 33355201
doi: 10.1124/dmd.120.000294
Covinsky JO, Russo J Jr, Kelly KL, Cashman J, Amick EN, Mason WD. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers. J Clin Pharmacol. 1979;19(5–6):261–9.
pubmed: 469022
doi: 10.1002/j.1552-4604.1979.tb02479.x
Ochs HR, Greenblatt DJ, Woo E, Franke K, Pfeifer HJ, Smith TW. Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. Am J Cardiol. 1978;41(4):770–7.
pubmed: 645583
doi: 10.1016/0002-9149(78)90830-5
Farkas E, Kiss D, Zelko R. Study on the release of chlorhexidine base and salts from different liquid crystalline structures. Int J Pharm. 2007;340(1–2):71–5.
pubmed: 17467206
doi: 10.1016/j.ijpharm.2007.03.038
pmcid: 17467206
Zeng P, Rao A, Wiedmann TS, Bowles W. Solubility properties of chlorhexidine salts. Drug Dev Ind Pharm. 2009;35(2):172–6.
pubmed: 18785046
doi: 10.1080/03639040802220318
pmcid: 18785046
Buchanan LV, Thompson DD, Hsu CYL, Walters RR, Gibson JK. Antiarrhythmic and electrophysiologic effects of sublingual ibutilide fumarate. Drug Dev Res. 1995;34:322–8.
doi: 10.1002/ddr.430340403
Wood MA, Clemo HS, Ellenbogen KA. Drug evaluation cardiovascular & renal: Ibutilide fumarate: a new class III agent for termination of atrial fibrillation and atrial flutter. Expert Opin Investig Drugs. 1996;5:1511–22.
doi: 10.1517/13543784.5.11.1511
Warawa EJ, Migler BM. Preparation of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4]thiazepine as a neuroleptic and antipsychotic. In. USA: ICI Americas, Inc.; 1987.
Pollak PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther. 2000;68(1):92–7.
pubmed: 10945320
doi: 10.1067/mcp.2000.107507
Volgyi G, Baka E, Box KJ, Comer JE, Takacs-Novak K. Study of pH-dependent solubility of organic bases. Revisit of Henderson-Hasselbalch relationship. Anal Chim Acta. 2010;673(1):40–6.
pubmed: 20630176
doi: 10.1016/j.aca.2010.05.022
Garbacz G, Kandzi A, Koziolek M, Mazgalski J, Weitschies W. Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions. AAPS PharmSciTech. 2014;15(1):230–6.
pubmed: 24297600
doi: 10.1208/s12249-013-0050-2
Harada S, Takahashi Y, Nakagawa H. Transdermal administration of emedastine. Biol Pharm Bull. 1993;16(9):884–8.
pubmed: 7903575
doi: 10.1248/bpb.16.884
Yanni JM, Robertson SM, Okumura S, Tanaka H, Saito T. Ophthalmic compositions comprising Emedastine and methods for their use. In. Fort Worth, Texas: Alcon Laboratories, Inc.; 1995.
Mock S, Dmochowski RR. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. Expert Opin Drug Metab Toxicol. 2013;9(12):1659–66.
pubmed: 24205892
doi: 10.1517/17425255.2013.858118
Kerekes P, Nemethne Racz C, Hajko J, Aronhime J, Szabo C, Tamas T, Gavenda A, Kovacsne Mezei A. Crystalline forms of fesoterodine fumarate and fesoterodine base. US20120220655A1 (Sept 03, 2010), Teva Pharmaceuticals Works PLC; 2011.
Anonymous. https://www.ema.europa.eu/en/documents/assessment-report/cotellic-epar-public-assessment-report_en.pdf . Accessed 19 Jan 2021
Kothari S, Mantik P, Mauerer A, Rezaei H. A process for preparing immediate-release tablets containing a drug. WO2017004122A1 (June 29, 2016), Genentech, Inc.; 2017.
Anonymous. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000ChemR.pdf . Accessed 19 Jan.
Box KJ, Volgyi G, Baka E, Stuart M, Takacs-Novak K, Comer JE. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution--a validation study. J Pharm Sci. 2006;95(6):1298–307.
pubmed: 16552741
doi: 10.1002/jps.20613
pmcid: 16552741
Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L, et al. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorg Med Chem Lett. 2010;20(24):7312–6.
pubmed: 21055935
doi: 10.1016/j.bmcl.2010.10.068
pmcid: 21055935
Kwon JW, Armbrust KL. Aqueous solubility, n-octanol-water partition coefficient, and sorption of five selective serotonin reuptake inhibitors to sediments and soils. Bull Environ Contam Toxicol. 2008;81(2):128–35.
pubmed: 18389163
doi: 10.1007/s00128-008-9401-1
pmcid: 18389163
Campbell SF, Cross PE, Stubbs JK. Dihydropyridine anti-ischemic and antihypertensive agents and pharmaceutical compositions containing them. DE3366920D1 (March 08, 2983), Pfizer Ltd.; 1983.
Gunaydin H. Probabilistic approach to generating MPOs and its application as a scoring function for CNS drugs. ACS Med Chem Lett. 2016;7(1):89–93.
pubmed: 26819672
doi: 10.1021/acsmedchemlett.5b00390
pmcid: 26819672
Mignini F, Tomassoni D, Traini E, Amenta F. Single-dose, randomized, crossover bioequivalence study of amlodipine maleate versus amlodipine besylate in healthy volunteers. Clin Exp Hypertens. 2007;29(8):539–52.
pubmed: 18058479
doi: 10.1080/10641960701744046
pmcid: 18058479
Lu Q, Ku MS, Chew W, Cheal GK, Hadfield AF, Mirmehrabi M. Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof. WO2009052264A3 (Oct 16, 2008), Wyeth Corp; 2008.
Chen M, Zhang Y, Diao X, Zhang X. New crystal form of neratinib maleate and preparation method therefor. WO2016110270A1 (Jan 08, 2016), Crystal PharmaTech Co., Ltd.; 2016.
Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett. 2012;3(2):106–11.
pubmed: 24900436
doi: 10.1021/ml2002423
Shaik N, Hee B, Wei H, LaBadie RR. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study. Cancer Chemother Pharmacol. 2019;83(3):463–72.
pubmed: 30536154
doi: 10.1007/s00280-018-3748-8
Anonymous. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf . Accessed 19 Jan 2021
Anonymous. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf . Accessed 19 Jan 2021
Chakole DD. Stabilized Pharmaceutical Formulations Containing Amlodipine Maleate. WO2003032954 A1 (July 18, 2002), Dr. Reddy's Laboratories Ltd.; 2003.
Stepanovs D, Jure M, Gosteva M, Popelis J, Kiselovs G, Mishnev A. Crystal structures and physicochemical properties of diltiazem base and its acetylsalicylate, nicotinate and L-malate salts. CrystEngComm. 2016;18:1235–41.
doi: 10.1039/C5CE01204J
Carl D, Huttrer CP, Scholz CR. Tertiary amines of heterocyclic compounds. US2406594A (Dec 23, 1943), Ciba Pharm. Prod. Inc.; 1946.
Kiningham KK. Tripelennamine. In: Enna SJ, Bylund DB, editors. xPharm: The Comprehensive Pharmacology Reference: Elsevier Inc.; 2007. p. 1–4.
Af Ursin K, Salmia J, Niskanen H, Kortesuo P, Kananen M, Kiesvaara J, et al. Soluble compositions of toremifene. EP1140197B1 (Dec 16, 1999), Orion Oyj; 1999.
Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm. 2006;313(1–2):144–9.
pubmed: 16516418
doi: 10.1016/j.ijpharm.2006.01.028
pmcid: 16516418
Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, Brockmoller J, Tzvetkov MV. Opioids as substrates and inhibitors of the genetically highly variable organic cation transporter OCT1. J Med Chem. 2019;62(21):9890–905.
pubmed: 31597043
doi: 10.1021/acs.jmedchem.9b01301
pmcid: 31597043
Miranda C, Perez-Rodriguez Z, Hernandez-Armengol R, Quinones-Garcia Y, Betancourt-Puron T, Cabrera-Perez MA. Biowaiver or bioequivalence: ambiguity in sildenafil citrate BCS classification. AAPS PharmSciTech. 2018;19(4):1693–8.
pubmed: 29532425
doi: 10.1208/s12249-018-0982-7
pmcid: 29532425
Jung SY, Seo YG, Kim GK, Woo JS, Yong CS, Choi HG. Comparison of the solubility and pharmacokinetics of sildenafil salts. Arch Pharm Res. 2011;34(3):451–4.
pubmed: 21547677
doi: 10.1007/s12272-011-0313-y
Zubair MU, Mahmoud M.A. Hassan a, Al-Meshat IA. Caffeine. In: Florey K, editor. Analytical Profiles of Drug Substances: Academic Press; 1986. p. 71–150.
Gurau G, Kelley SP, Bona KRD, Smiglak M, Rogers RD. Anhydrous caffeine hydrochloride and its hydration. Cryst Growth Des. 2012;12:4658–62.
doi: 10.1021/cg300878j
Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K. Clinical pharmacology of Ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet. 2019;58(4):431–49.
pubmed: 30117017
doi: 10.1007/s40262-018-0702-1
Shirley M. Ixazomib: First global approval. Drugs. 2016;76(3):405–11.
Valik M, Gabriel R, Vraspir P, Lukas D. Solid state forms of ixazomib citrate. US10604537B2 (June 08, 2017), Teva Pharmaceuticals International GmbH; 2017.
Krise JP, Narisawa S, Stella VJ. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J Pharm Sci. 1999;88(9):922–7.
pubmed: 10479355
doi: 10.1021/js9803813
Talbert RL. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev. 2004;9(2):131–7.
pubmed: 15516861
doi: 10.1023/B:HREV.0000046368.08825.20
Paoli P, Rossi P, Macedi E, Ienco A, Chelazzi L, Bartolucci GL, Bruni B. Similar but different: The case of metoprolol tartrate and succinate salts. Cryst Growth Des. 2016;16(2):789–99.
Sandberg A, Abrahamsson B, Regardh CG, Wieselgren I, Bergstrand R. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol. 1990;30(S2):S2–16.
pubmed: 2179280
doi: 10.1002/j.1552-4604.1990.tb03490.x
Kendall MJ. Metoprolol-controlled release, zero order kinetics. J Clin Pharm Ther. 1989;14(3):159–79.
pubmed: 2668307
doi: 10.1111/j.1365-2710.1989.tb00235.x
Tangeman HJ, Patterson JH. Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother. 2003;37(5):701–10.
pubmed: 12708950
doi: 10.1345/aph.1C286
Dowle MD, Coates IH. Indoles. GB2124210A (June 07, 1983), Glaxo Group Ltd.; 1983.
Paczkowska M, Mizera M, Salat K, Furgala A, Popik P, Knapik-Kowalczuk J, et al. Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins. Sci Rep. 2018;8(1):16184.
pubmed: 30385844
pmcid: 6212534
doi: 10.1038/s41598-018-34554-w
Suh YH, Cho YD, Lyu CS, Yoon MY, Choi HY, Han SK. Stable pharmaceutical composition comprising solifenacin, and method for preparing the same. WO2015115750 (Jan 22, 2015), CJ HealthCare Corporation; 2015.
Sugihara A, Yasuji T, Masaki K, Murayama D. Composition for solid pharmaceutical preparation of solifenacin or salt thereof. EP1728791A4 (March 24, 2005), Astellas Pharma Inc.; 2005.
Fuentes GG, Bonde-Larsen AL, Lopez-Bachiller JDC, Rodriguez CS, Sainz YF. Solifenacin salts. WO2012004264A1 (July 05, 2011), Ragactives, S.L.U.; 2012.
Samant TS, Dhuria S, Lu Y, Laisney M, Yang S, Grandeury A, et al. Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations. Clin Pharmacol Ther. 2018;104(2):374–83.
pubmed: 29134635
doi: 10.1002/cpt.940
Rao DM, Venugopal B. Processes for the preparation of highly pure prucalopride succinate and its intermediates. WO2017137910A1 (Feb 09, 2017), Symed Labs Limited; 2017.
Sheng X, Sheng X, Jiang X. Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof. US10669256B2 (Nov 11, 2016), Hangzhou Solipharma Co Ltd.; 2016.
Criswick VG, Drance SM. Comparative study of four different epinephrine salts on intraocular pressure. Arch Ophthalmol. 1966;75(6):768–70.
pubmed: 5327792
doi: 10.1001/archopht.1966.00970050770010
pmcid: 5327792
Sciarra JJ, Patel JM, Kapoor AL. Synthesis and formulation of several epinephrine salts as an aerosol dosage form. J Pharm Sci. 1972;61(2):219–23.
pubmed: 5059786
doi: 10.1002/jps.2600610216
pmcid: 5059786
Foda NH, Ali SM. Zolpidem tartrate. Profiles Drug Subst Excip Relat Methodol 2012;37:413–438.
Schneider JA, Clark KF, Greene AA, Reisch JS, Markello TC, Gahl WA, et al. Recent advances in the treatment of cystinosis. J Inherit Metab Dis. 1995;18(4):387–97.
pubmed: 7494398
doi: 10.1007/BF00710051
pmcid: 7494398
Tothne Lauritz M, Volk B, Kataine Fadgyas K, Varga Z, Nagy T, Dietrich AD, Molnarne Samu E, Keszthelyi A, Racz N, Szlavik L. Pimavanserin salts useful for the production of a pharmaceutical preparation. WO2018007842A1 (July 07, 2017), Egis Gyogyszergyar Zrt.; 2018.
Anonymous. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200677lbl.pdf (Accessed on: May 22, 2021).
David TM, Ivan M. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design. J Pharm Pharmacol. 2015;67:782–802.
doi: 10.1111/jphp.12375
Matsumoto T, Wolferth CC Jr, Hayes MF. Methenamine salts as topical antibacterial agent. I. Experimental studies for burn and crush wound. Arch Surg. 1970;101(1):71–7.
pubmed: 4911675
doi: 10.1001/archsurg.1970.01340250073016
pmcid: 4911675
Kim S-D, Kang W, Lee HW, Park DJ, Ahn JH, Kim MJ, et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, openlabel, crossover study in healthy korean male subjects. Clin Ther. 2009;31:793–803.
pubmed: 19446152
doi: 10.1016/j.clinthera.2009.04.017
pmcid: 19446152
Kim B-H, Kim J-R, Lim KS, Shin H-S, Yoon SH, Cho J-Y, et al. Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy korean subjects. Clin Drug Investig. 2012;32:817–26.
pubmed: 23026843
doi: 10.1007/s40261-012-0007-3
pmcid: 23026843
Lasorella S, Porto R, Iezzi ML, Pistone C, Marseglia GL, Verrotti A, et al. Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of central precocious puberty (CPP): a retrospective study. Gynecol Endocrinol. 2020;36(4):338–40.
pubmed: 31441342
doi: 10.1080/09513590.2019.1655726
pmcid: 31441342
Bunnell CA, Ferguson TH, Hendriksen BA, Sanchez-Felix MV, Tupper DE. 2-Methyl-thieno-benzodiazepine formulation; US6169084B1 (Sept 30, 1998), Eli Lilly and co.; 1998.
Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140–50.
pubmed: 18834452
doi: 10.1111/j.1742-1241.2008.01900.x
pmcid: 18834452
Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat. 2010;6:573–81.
pubmed: 20856920
pmcid: 2938306
doi: 10.2147/NDT.S5463